[{"indications": "Indications\u00a0adjunct in stable patients with left\r\nventricular dysfunction with evidence of heart failure, following\r\nmyocardial infarction (start therapy within 3\u201314 days of event)", "name": "EPLERENONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.2 Diuretics", "2.2.3 Potassium-sparing diuretics and aldosterone antagonists", "Aldosterone antagonists", "EPLERENONE"], "cautions": "Cautions\u00a0measure plasma-potassium concentration\r\nbefore treatment, during initiation, and when dose changed; elderly; interactions: Appendix 1 (diuretics)", "side-effects": "Side-effects\u00a0diarrhoea, nausea; hypotension; dizziness; hyperkalaemia;\r\nrash; less commonly flatulence, vomiting, atrial\r\nfibrillation, postural hypotension, arterial thrombosis, dyslipidaemia,\r\npharyngitis, headache, insomnia, gynaecomastia, pyelonephritis, hyponatraemia,\r\ndehydration, eosinophilia, asthenia, malaise, back pain, leg cramps,\r\nimpaired renal function, azotaemia, sweating and pruritus", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129018.htm", "doses": ["Initially 25\u00a0mg once daily, increased within 4 weeks to\r\n50\u00a0mg once daily; child not recommended"], "pregnancy": "Pregnancy\u00a0manufacturer advises caution\u2014no information available"}]